The TiTKI Project - evaluation of the risk of thrombosis associated with the use of tyrosine kinase inhibitors

Project: Research

Project Details

StatusActive
Effective start/end date1/09/15 → …
View all
View less

Research Output

An updated meta-analysis of the risks of arterial and venous occlusive events with new generation BCR-ABL TKIs in patients with chronic myeloid leukemia

Haguet, H., Mullier, F., Graux, C., Dogne, J-M. & Douxfils, J., 13 Jun 2019.

Research output: Contribution to conference › Poster

In vitro investigations of the effect of BCR-ABL Tyrosine Kinase Inhibitors on endothelial cell viability

Haguet, H., Graux, C., Dogne, J-M., Mullier, F. & Douxfils, J., Jan 2019.

Research output: Contribution to conference › Poster

BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?

Haguet, H., Douxfils, J., Chatelain, C., Graux, C., Mullier, F. & Dogne, J-M., 2018, In : TH Open. 02, 1, p. e68-e88

Research output: Contribution to journal › Review article

Open Access
File
1 Downloads (Pure)

Activities

  • 6 Oral presentation
  • 1 Invited talk

Mécanismes thrombotiques des inhibiteurs de tyrosine kinase ciblant BCR-ABL

Hélène Haguet (Speaker), Jonathan Douxfils (Speaker), François Mullier (Speaker), Christian Chatelain (Speaker), Carlos Graux (Speaker), Jean-Michel Dogne (Speaker)
21 Mar 2019

Activity: Talk or presentation types › Oral presentation

The Namur Thrombosis and Hemostasis Center A gathering of experts from laboratory, clinical and regulatory field

Jonathan Douxfils (Invited speaker)
19 Mar 2019

Activity: Talk or presentation types › Invited talk

In vitro effects of BCR-ABL TKIs on endothelial cell survival and functions

Hélène Haguet (Speaker), Jonathan Douxfils (Speaker), Christian Chatelain (Speaker), Carlos Graux (Speaker), François Mullier (Speaker), Jean-Michel Dogne (Speaker)
9 Feb 2018

Activity: Talk or presentation types › Oral presentation